Latest news | Leukaemia Foundation - Page 5

Latest news

CAR-T therapy receives Federal Government funding allowing young people with ALL to receive innovative treatment

Monday, 15 April 2019,


The Leukaemia Foundation has welcomed today’s announcement by Federal Health Minister Greg Hunt to list CAR-T therapy on the Medicare Benefits Schedule (MBS). The treatment will be for use in paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant,

Read More

Welcome commitment to reduce out-of-pocket cancer costs

Friday, 05 April 2019


The Leukaemia Foundation welcomes Federal Labor’s commitment to reducing out-of-pocket costs for cancer patients as part of a $2.3 billion funding package announced in last night’s Federal Budget reply.  

The announcement includes funding to remove out-of-pocket costs associated with diagnostic imaging, bulk-billed Medicare items for oncologists and specialist surgeons,

Read More

New PBS listing vital to Australians living with B-cell Acute Lymphoblastic Leukaemia

Thursday, 4 April 2019


The Leukaemia Foundation has welcomed news Australians living with B-cell acute lymphoblastic leukaemia (B-ALL) will have access to the drug inotuzumab ozogamicin (Besponsa®) through the Pharmaceutical Benefits Scheme (PBS) after the listing was announced in this week’s Federal Budget.

According to the Federal Government, Australians living with

Read More

New Australian facilities announced for break-through CAR-T therapy and other immunotherapy clinical trials

Tuesday, 26 March 2019


The Leukaemia Foundation welcomes the federal government $80 million investment to establish the Peter MacCallum Centre as a new base for Car-T Cell therapy and other immunotherapy clinical trials in Australia. 

The funding package would help to build 2,600 square met facilities to manufacture commercial CAR-T

Read More

Leukaemia Foundation to partner with Tour de Cure for the inaugural Life Ride

Tuesday, 26 March 2019


The Leukaemia Foundation and Tour de Cure will combine forces in 2019 to host the first Life Ride – an inspiring three-day cycling event to help fund research and find a cure for blood cancer.

The inaugural Life Ride will be held in the spectacular Margaret River region of Western Australia from Sunday,

Read More

Treatment for cutaneous T-cell lymphomas to be subsidised through broadened PBS listing

Thursday, 21 March 2019


The Leukaemia Foundation welcomes the Federal Government’s announcement that the Pharmaceutical Benefits Scheme (PBS) listing of brentuximab vedotin (Adcetris®) will be broadened to include treatment of cutaneous T-cell lymphomas (CTCL) from 1 April 2019.

CTCL is a type of non-Hodgkin lymphoma that directly attacks the body’s T-cells, a type of white

Read More

Leukaemia Foundation supports Australian women #BalanceForBetter

Thursday, 07 March 2019


The Leukaemia Foundation is proud to support International Women’s Day, a day to acknowledge and celebrate the social, economic, cultural and political achievements of all women across the globe.

This year, the Leukaemia Foundation is thrilled to recognise two innovative Australian Clinical and Science PhD female investigators, whose work is at the forefront of next generation medical

Read More

Hair recycling partnership shaving environment while tackling blood cancer

Friday, 01 March 2019


Social enterprise Sustainable Salons is once again throwing its support behind the Leukaemia Foundation’s World’s Greatest Shave by recycling hundreds of kilograms of hair to be donated for wigs and environmental hair booms thanks to Australia’s brave shavers.

For the second year running, Sustainable Salons are uniting

Read More

Breakthrough chronic lymphocytic leukaemia (CLL) treatment now available for Australians 

Monday, 25 February 2019


The Leukaemia Foundation welcomes the Federal Government’s announcement that the targeted cancer treatment Venetoclax (Venclexta®), will be added to Pharmaceutical Benefits Scheme (PBS) from 1 March 2019. 

Venetoclax will be available in combination with rituximab for patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia

Read More


Wednesday, 30 January 2019


Warwick local and Leukaemia Foundation volunteer, Elaine Stewart was recognised for her vital service and support of Australians living with blood cancer. 

Elaine Stewart was awarded an Order of Australia Medal for her selfless work and contribution to the Leukaemia Foundation’s Warwick Branch, as well as her local School’s Chaplaincy Committee and the Riding for the Disabled Association. 

A volunteer for more than

Read More

Share this page